Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
13
TRAW Quote, Financials, Valuation and Earnings
Last price:
$1.24
Seasonality move
:
7.56%
Day range:
$1.39 - $2.20
52-week range:
$0.97 - $19.44
Dividend yield:
0%
P/E ratio:
0.05x
P/S ratio:
2.78x
P/B ratio:
2.18x
Volume:
4.5M
Avg. volume:
593.7K
1-year change:
-72.39%
Market cap:
$9.9M
Revenue:
$226K
EPS (TTM):
$24.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TRAW
Traws Pharma, Inc.
|
-- | -- | -100% | -- | $8.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TRAW
Traws Pharma, Inc.
|
$1.24 | $8.00 | $9.9M | 0.05x | $0.00 | 0% | 2.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3.50 | $0.85 | $441M | 5.88x | $0.80 | 0% | 6.80x |
|
NNVC
NanoViricides, Inc.
|
$1.24 | $6.50 | $22.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.82 | $2.00 | $678.8K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.18 | $7.00 | $6.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TRAW
Traws Pharma, Inc.
|
-- | 1.382 | -- | 1.07x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TRAW
Traws Pharma, Inc.
|
-$15K | -$4.1M | -124.39% | -124.39% | -45.7% | -$4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Traws Pharma, Inc. vs. Competitors
-
Which has Higher Returns TRAW or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -22.87% compared to Traws Pharma, Inc.'s net margin of -255.85%. Traws Pharma, Inc.'s return on equity of -124.39% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital TRAWTraws Pharma, Inc.99.96% -$0.34 $4.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About TRAW or NBY?
Traws Pharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -75.71%. Given that Traws Pharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Traws Pharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRAWTraws Pharma, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is TRAW or NBY More Risky?
Traws Pharma, Inc. has a beta of 1.745, which suggesting that the stock is 74.453% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock TRAW or NBY?
Traws Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Traws Pharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRAW or NBY?
Traws Pharma, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Traws Pharma, Inc.'s net income of -$3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Traws Pharma, Inc.'s price-to-earnings ratio is 0.05x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma, Inc. is 2.78x versus 6.80x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRAWTraws Pharma, Inc.2.78x 0.05x -- -$3M NBYNovaBay Pharmaceuticals, Inc.6.80x 5.88x $521K -$1.3M
-
Which has Higher Returns TRAW or NNVC?
NanoViricides, Inc. has a net margin of -22.87% compared to Traws Pharma, Inc.'s net margin of --. Traws Pharma, Inc.'s return on equity of -124.39% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital TRAWTraws Pharma, Inc.99.96% -$0.34 $4.5M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About TRAW or NNVC?
Traws Pharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 424.19%. Given that Traws Pharma, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Traws Pharma, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRAWTraws Pharma, Inc.1 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is TRAW or NNVC More Risky?
Traws Pharma, Inc. has a beta of 1.745, which suggesting that the stock is 74.453% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock TRAW or NNVC?
Traws Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRAW or NNVC?
Traws Pharma, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Traws Pharma, Inc.'s net income of -$3M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Traws Pharma, Inc.'s price-to-earnings ratio is 0.05x while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma, Inc. is 2.78x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRAWTraws Pharma, Inc.2.78x 0.05x -- -$3M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns TRAW or OGEN?
Oragenics, Inc. has a net margin of -22.87% compared to Traws Pharma, Inc.'s net margin of --. Traws Pharma, Inc.'s return on equity of -124.39% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital TRAWTraws Pharma, Inc.99.96% -$0.34 $4.5M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About TRAW or OGEN?
Traws Pharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 142.45%. Given that Traws Pharma, Inc. has higher upside potential than Oragenics, Inc., analysts believe Traws Pharma, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRAWTraws Pharma, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is TRAW or OGEN More Risky?
Traws Pharma, Inc. has a beta of 1.745, which suggesting that the stock is 74.453% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock TRAW or OGEN?
Traws Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRAW or OGEN?
Traws Pharma, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Traws Pharma, Inc.'s net income of -$3M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Traws Pharma, Inc.'s price-to-earnings ratio is 0.05x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma, Inc. is 2.78x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRAWTraws Pharma, Inc.2.78x 0.05x -- -$3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns TRAW or PTN?
Palatin Technologies has a net margin of -22.87% compared to Traws Pharma, Inc.'s net margin of --. Traws Pharma, Inc.'s return on equity of -124.39% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRAWTraws Pharma, Inc.99.96% -$0.34 $4.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About TRAW or PTN?
Traws Pharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Traws Pharma, Inc., analysts believe Palatin Technologies is more attractive than Traws Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRAWTraws Pharma, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is TRAW or PTN More Risky?
Traws Pharma, Inc. has a beta of 1.745, which suggesting that the stock is 74.453% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock TRAW or PTN?
Traws Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRAW or PTN?
Traws Pharma, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Traws Pharma, Inc.'s net income of -$3M is higher than Palatin Technologies's net income of --. Notably, Traws Pharma, Inc.'s price-to-earnings ratio is 0.05x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma, Inc. is 2.78x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRAWTraws Pharma, Inc.2.78x 0.05x -- -$3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns TRAW or TOVX?
Theriva Biologics, Inc. has a net margin of -22.87% compared to Traws Pharma, Inc.'s net margin of --. Traws Pharma, Inc.'s return on equity of -124.39% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital TRAWTraws Pharma, Inc.99.96% -$0.34 $4.5M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About TRAW or TOVX?
Traws Pharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 471.43%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3716.79%. Given that Theriva Biologics, Inc. has higher upside potential than Traws Pharma, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Traws Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRAWTraws Pharma, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is TRAW or TOVX More Risky?
Traws Pharma, Inc. has a beta of 1.745, which suggesting that the stock is 74.453% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock TRAW or TOVX?
Traws Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRAW or TOVX?
Traws Pharma, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Traws Pharma, Inc.'s net income of -$3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Traws Pharma, Inc.'s price-to-earnings ratio is 0.05x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma, Inc. is 2.78x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRAWTraws Pharma, Inc.2.78x 0.05x -- -$3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 37x
Alerts
Sell
46
BE alert for Dec 18
Bloom Energy Corp. [BE] is up 4.27% over the past day.
Sell
44
STRL alert for Dec 18
Sterling Infrastructure, Inc. [STRL] is up 6.62% over the past day.
Sell
39
SOXL alert for Dec 18
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 7.28% over the past day.
